FIT Cancer 11 11th FORUM ON Translational Immunology and IMMUNOTHERAPY OF CANCER 26 CP-45. EFFICIENT IN VIVO ANTI-TUMORAL EFFECT OF THE ANTI-CEA, GRANULYSIN-BASED IMMUNOTOXIN MFE23GRNLY IN A LUNG ADENOCARCINOMA MODEL. COMBINATION WITH A BCL-XL-SELECTIVE BH3 MIMETIC Alberto Anel Bernal1, Raquel Ibáñez Pérez1, Ana Pilar Tobajas de la Fuente1, Patricia Guerrero Ochoa1, Ruth Soler Agesta1, Isabel Marzo Rubio1, Javier Naval Iraberri1, Laura Sanz Alcober2 1Universidad de Zaragoza. Zaragoza. 2Hospital Universitario Puerta de Hierro Majadahonda. Majadahonda, Madrid CP-46. CHARACTERIZATION OF A MONOCLONAL ANTIBODY FOR PATIENT-TAILORED IMMUNOTHERAPY IN SÉZARY SYNDROME Marta Herrero Alonso1, Ana V. Marín Marín1, Rebeca Fernández Megino1, Iván Estévez Benito1, Nikolas Valencia Salcedo1, Laura Jiménez Villegas1, Mercedes Domínguez Rodríguez2, Inmaculada Moreno Iruela2, María Luisa Gaspar Alonso-Vega2, Isabel Cortegano Jimeno2, Marcos Viñuela Martín3, Irene Real Arévalo3, José Luis Subiza4, Pablo Ortiz Romero5, Balbino Alarcón6, José R. Regueiro Barros1 1Department of Immunology, Ophthalmology and ENT. School of Medicine. Universidad Complutense de Madrid. 12 de Octubre Health Research Institute (i+12). Madrid. 2Servicio de Inmunología Microbiana. Centro Nacional de Microbiología. Instituto de Investigación Carlos III. Madrid. 3Clinical Immunology-Experimental and Surgery Department. Hospital Clínico Universitario San Carlos. Madrid. 4Inmunotek S. L. Alcalá de Henares, Madrid. 5Dermatology Department. Hospital Universitario 12 de Octubre. Madrid. 6Centre for Molecular Biology Severo Ochoa. Spanish National Research Council (CSIC). Madrid CP-47. OPTIMIZATION OF NEOANTIGEN-SPECIFIC TCR IDENTIFICATION FOR PERSONALIZED THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA Andrea Arán Garriga1, Roberto Martínez Soler1, Berta Casanovas Albertí1, Alejandro Ramírez Chacón1, Iván García Loza1, E. Azucena González Navarro2, Manel Juan Otero2, 1Fundació de Recerca Clínic Barcelona. IDIBAPS. Barcelona. 2Servei d’Immunolgia. Centre de Diagnòstic Biomèdic (CDB). Hospital Clínic de Barcelona. Barcelona 11:45-12:45 Session VII: New targets for immunotherapies Chairs: Dr. Javier de Castro Carpeño Hospital Universitario La Paz. Madrid Dra. Ana Arance Fernández Hospital Clinic de Barcelona. Barcelona 11:45-12:00 Bispecific Trimerbodies: New Hope for Immunostimulation Dra. Marta Compte Grau Leadartis S.L. Madrid 12:00-12:15 The third immune-checkpoint: LAG3 Dra. Teresa Ramírez Montagut Regeneron Pharmaceuticals Inc. 12:15-12:30 TCR therapeutics: Tebentafusp and beyond Dr. Enrique Espinosa Arranz Hospital Universitario La Paz. Madrid
RkJQdWJsaXNoZXIy OTI4NTYw